PL2655375T3 - Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie - Google Patents
Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanieInfo
- Publication number
- PL2655375T3 PL2655375T3 PL11799724T PL11799724T PL2655375T3 PL 2655375 T3 PL2655375 T3 PL 2655375T3 PL 11799724 T PL11799724 T PL 11799724T PL 11799724 T PL11799724 T PL 11799724T PL 2655375 T3 PL2655375 T3 PL 2655375T3
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- pharmaceutical use
- pyrimidinone derivatives
- pyrimidinone
- derivatives
- Prior art date
Links
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1061197A FR2969613B1 (fr) | 2010-12-23 | 2010-12-23 | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique |
| FR1061194A FR2969612B1 (fr) | 2010-12-23 | 2010-12-23 | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique |
| EP11799724.7A EP2655375B1 (fr) | 2010-12-23 | 2011-12-22 | Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique |
| PCT/EP2011/073874 WO2012085244A1 (fr) | 2010-12-23 | 2011-12-22 | Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2655375T3 true PL2655375T3 (pl) | 2015-05-29 |
Family
ID=45401087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11799724T PL2655375T3 (pl) | 2010-12-23 | 2011-12-22 | Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8815853B2 (pl) |
| EP (1) | EP2655375B1 (pl) |
| CY (1) | CY1116100T1 (pl) |
| DK (1) | DK2655375T3 (pl) |
| ES (1) | ES2531465T3 (pl) |
| HR (1) | HRP20150235T1 (pl) |
| HU (1) | HUE024504T2 (pl) |
| PL (1) | PL2655375T3 (pl) |
| PT (1) | PT2655375E (pl) |
| SI (1) | SI2655375T1 (pl) |
| WO (1) | WO2012085244A1 (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2992316A1 (fr) | 2012-06-22 | 2013-12-27 | Sanofi Sa | Derives de pyrimidinones, leur preparation et leur application en therapeutique |
| FR2992314B1 (fr) * | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| ME03557B (me) | 2013-03-15 | 2020-07-20 | G1 Therapeutics Inc | Privremena zaštiтa normalnih ćelija током hemoterapije |
| CA2906157C (en) | 2013-03-15 | 2022-05-17 | G1 Therapeutics, Inc. | Highly active anti-neoplastic and anti-proliferative agents |
| WO2015108861A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2015161288A1 (en) * | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| ES2821400T3 (es) | 2016-02-19 | 2021-04-26 | Sprint Bioscience Ab | Compuestos de 6-heterociclil-4-morfolin-4-ilpiridin-2-ona útiles para el tratamiento del cáncer y la diabetes |
| TWI721104B (zh) | 2016-02-19 | 2021-03-11 | 瑞典商斯普林特生物科技公司 | 6‐芳基或6‐雜芳基‐4‐嗎啉‐4‐芳基‐吡啶‐2‐酮化合物 |
| JP7199737B2 (ja) | 2017-08-23 | 2023-01-06 | スプリント バイオサイエンス アクティエボラーグ | ピリジルピリドン化合物 |
| SI3672962T1 (sl) * | 2017-08-23 | 2022-06-30 | Sprint Bioscience Ab | Morfolinilpiridonske spojine |
| TW202325302A (zh) | 2017-08-23 | 2023-07-01 | 瑞典商斯普林特生物科技公司 | 吡啶胺-吡啶酮及嘧啶胺-吡啶酮化合物 |
| SI3672967T1 (sl) | 2017-08-23 | 2022-04-29 | Sprint Bioscience Ab | Spojine azaindolilpiridona in diazaindolilpiridona |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| WO2022093820A1 (en) * | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Substituted morpholine compounds |
| CN115448921B (zh) * | 2021-06-08 | 2023-08-01 | 四川大学 | 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1891693A (zh) | 2000-01-24 | 2007-01-10 | 基纳西亚股份有限公司 | 用于治疗的吗啉代基取代的化合物 |
| AR030587A1 (es) * | 2000-09-01 | 2003-08-27 | Sanofi Aventis | Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona y 7-piridinil-2,3-dihidroimidazo[1,2-a]pirimidin-5(1h)-ona |
| GB0119865D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| CA2457965C (en) | 2001-09-21 | 2010-06-01 | Sanofi-Synthelabo | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives |
| EP1340761A1 (en) | 2002-02-28 | 2003-09-03 | Sanofi-Synthelabo | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| KR100984595B1 (ko) | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체 |
| US7598377B2 (en) | 2002-08-16 | 2009-10-06 | Astrazeneca Ab | Inhibition of phosphoinositide 3-kinase β |
| EP1454909B1 (en) | 2003-03-07 | 2008-08-20 | Sanofi Aventis | 8'-pyridinyl-dihydrospiro- (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one derivatives and their use against neurodegenerative diseases |
| EP1460076A1 (en) | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
| EP1557417B1 (en) | 2003-12-19 | 2007-03-07 | Sanofi-Aventis | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives |
| AR053358A1 (es) | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
| US20090035394A1 (en) | 2005-05-26 | 2009-02-05 | Graeme Cameron Murray Smith | Use of dna-pk inhibition to sensitise atm deficient cancers to dna-damaging cancer therapies |
| KR20090025358A (ko) | 2006-07-24 | 2009-03-10 | 에프. 호프만-라 로슈 아게 | 글루코키나제 활성화제로서의 피라졸 |
| WO2008064244A2 (en) | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
| WO2008148074A2 (en) | 2007-05-24 | 2008-12-04 | Research Foundation Of State University Of New York | Inhibitors of mtor and methods of treatment using same |
| RU2010133715A (ru) | 2008-01-25 | 2012-02-27 | Астразенека Аб (Se) | ЭНАНТИОМЕРНО ЧИСТАЯ (-)2-[1-(7-МЕТИЛ-2-(МОРФОЛИН-4-ИЛ)-4-ОКСО-4Н-ПИРИДО[1,2-a]ПИРИМИДИН-9-ИЛ)БЕНЗОЙНАЯ КИСЛОТА, ЕЕ ПРИМЕНЕНИЕ В ФАРМАКОТЕРАПИИ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕЕ |
| EP2253633A4 (en) | 2008-03-12 | 2012-02-29 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| CN102369205B (zh) | 2009-01-30 | 2014-10-29 | 武田药品工业株式会社 | 稠环化合物和其用途 |
| HUE034503T2 (en) | 2009-07-02 | 2018-02-28 | Sanofi Sa | 2,3-Dihydro-1-imidazo [1,2-a] pyrimidin-5-one derivatives, their preparation process and their use in medicine |
| CN102482286B (zh) | 2009-07-02 | 2015-07-15 | 赛诺菲 | 新型1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备以及其医药用途 |
-
2011
- 2011-12-22 DK DK11799724.7T patent/DK2655375T3/en active
- 2011-12-22 HR HRP20150235TT patent/HRP20150235T1/hr unknown
- 2011-12-22 PT PT11799724T patent/PT2655375E/pt unknown
- 2011-12-22 EP EP11799724.7A patent/EP2655375B1/fr active Active
- 2011-12-22 PL PL11799724T patent/PL2655375T3/pl unknown
- 2011-12-22 US US13/996,866 patent/US8815853B2/en active Active
- 2011-12-22 SI SI201130400T patent/SI2655375T1/sl unknown
- 2011-12-22 ES ES11799724.7T patent/ES2531465T3/es active Active
- 2011-12-22 HU HUE11799724A patent/HUE024504T2/en unknown
- 2011-12-22 WO PCT/EP2011/073874 patent/WO2012085244A1/fr not_active Ceased
-
2015
- 2015-03-03 CY CY20151100220T patent/CY1116100T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1116100T1 (el) | 2017-02-08 |
| US8815853B2 (en) | 2014-08-26 |
| ES2531465T3 (es) | 2015-03-16 |
| HUE024504T2 (en) | 2016-01-28 |
| US20130289031A1 (en) | 2013-10-31 |
| SI2655375T1 (sl) | 2015-03-31 |
| PT2655375E (pt) | 2015-03-02 |
| EP2655375A1 (fr) | 2013-10-30 |
| DK2655375T3 (en) | 2015-03-09 |
| HRP20150235T1 (hr) | 2015-04-24 |
| WO2012085244A1 (fr) | 2012-06-28 |
| EP2655375B1 (fr) | 2014-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2655375E (pt) | Derivados de pirimidinona, sua preparação e sua utilização farmacêutica | |
| IL266510B (en) | History of aminopyrimidines, their preparation and pharmaceutical preparations containing them | |
| IL231386A (en) | Pyrazolequinoline derivatives, their preparation and medical use | |
| ZA201300685B (en) | Anticancer derivatives,preparation thereof and therapeutic use thereof | |
| EP2604612A4 (en) | C-ARYL-GLUCOSIDE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | |
| IL231382A0 (en) | History of benzonitriles, their preparation containing them | |
| PL2562172T3 (pl) | Pochodne sfelaktonu, ich kompozycje farmaceutyczne, sposoby wytwarzania i zastosowania | |
| EP2481739A4 (en) | DIHYDROPTERIDINONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL USE | |
| IL223463A (en) | Urea History, Pharmaceutical Preparations Containing and Uses | |
| ZA201209739B (en) | Levocarrimycin,pharmaceutical compositions,preparation methods and uses thereof | |
| IL225824A0 (en) | History of quinoxaline, their preparation and pharmaceutical preparations containing them | |
| IL226094A0 (en) | The history of pyrazine, their preparation and pharmaceutical preparations containing them | |
| IL219888A0 (en) | Pyridine-pyridinone derivatives, preparation and therapeutic use thereof | |
| IL227404A0 (en) | Pyrimidine history, their preparation and pharmaceutical preparations containing them | |
| SI2448940T1 (sl) | Derivati 6,7,8,9-tetrahidro-pirimido(1,2-a)pirimidin-4-ona, njihova priprava in njihova farmacevtska uporaba | |
| IL233238A0 (en) | Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use | |
| ZA201107363B (en) | Quinazolinedione derivatives,preparation thereof and various therapeutic uses thereof | |
| IL228705A (en) | Derivatives of Reliable Phenoxy-Ethyl, Pharmaceutical Preparations Containing and Using Them | |
| IL225823A0 (en) | History of quinazoline, their preparation and pharmaceutical preparations containing them | |
| SI2421864T1 (sl) | 1-pirazolo(4,3-c)izokinolinski derivati, njihova priprava in njihova terapevtska uporaba | |
| ZA201501597B (en) | Macrolide derivatives,preparation thereof and therapeutic use thereof | |
| IL214544A0 (en) | Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation thereof, and therapeutic use thereof | |
| EP2621490A4 (en) | PROPARGYL-TRIFLUOROMETHOXY-AMINO-BENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | |
| IL225378A0 (en) | History of phenylquinazoline, their preparation and pharmaceutical preparations containing them | |
| IL226388A0 (en) | New indolizine derivatives, their preparation and medical use |